DCM
ADMA icon

Diag Capital Management’s ADMA Biologics ADMA Stock Holding History

Diag Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$435K Buy
+182,100
New +$902K 0.5% 35

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diag Capital Management's ADMA Position: Q4 2018 in Review

Diag Capital Management opened a new position in ADMA Biologics (ADMA) in Q4 2018: 182,100 shares worth $435K. The stake represents 0.5% of the portfolio and ranks #35 among its holdings.

52 funds tracked by Wall St. Rank hold ADMA as of Q4 2018.

  • Diag Capital Management held 182,100 shares of ADMA Biologics worth $435K as of Q4 2018.
  • ADMA Biologics was a new Diag Capital Management position in Q4 2018.
  • ADMA Biologics made up 0.5% of Diag Capital Management's portfolio in Q4 2018, its #35 holding.
  • 52 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.